Related Experiment Video
Updated: Jul 24, 2026

Isolation and Profiling of MicroRNA-containing Exosomes from Human Bile
Published on: June 13, 2016
Serum secretory component: a potential marker of biliary obstruction
Abstract:
Secretory Component (SC) was measured in serum samples from patients with a variety of disorders using enzyme-linked immunosorbent assay (ELISA). The overall precision of the method at high and low concentrations of SC was 11% (CV). Serum concentrations of SC were significantly higher in patients with several forms of liver disease (means = 82.37 mg/l +/- SD 56.9) compared with normals (means = 6.0 +/- SD 4.2), patients with diseases of mucosal surfaces (means = 7.4 mg/l +/- SD 4.2) and patients with elevated alkaline phosphatase due to causes other than overt liver disease (means = 16.4 mg/l +/- SD 7.6). Serum SC levels correlated strongly with serum alkaline phosphatase activity (rs = 0.648) in the presence of liver disease. Raised serum SC in liver disease probably reflects reflumeans of biliary SC and secretory IgA into blood due to cholestasis. Estimation of serum SC could be clinically useful as an index of biliary obstruction, especially to distinguish a raised serum alkaline phosphatase activity of liver or bone origin.
More Related Videos
08:42Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
Published on: November 27, 2016
07:44Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
Published on: March 25, 2022
Related Concept Videos
Bile
Bile is released when dietary fats enter...
Pancreatic Juice and Secretion
When acidic chyme from the stomach enters the duodenum, it triggers the release of secretin, a hormone that prompts pancreatic juice secretion. After a fatty meal, cholecystokinin, another hormone, stimulates gallbladder contraction and enhances enzyme-rich...
Serum Laboratory Studies, Stool Test, Breath Test
Hepatic Drug Excretion: Influencing Factors
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cholecystitis